Treace Medical Q4 revenue $68.7M (+10% YoY); net loss narrows to $0.5M; guides FY25 rev $224-230M

TREACE MEDICAL CONCEPTS, INC.

2024-FY EPS reported -$0.90 revenue$209,357,000

Q4 revenue $68.7M (+10% YoY); net loss ($0.5M) vs ($6.3M) in Q4 2023; adj. EBITDA $11.1M (322% improvement).
Full-year 2024 revenue $209.4M (+12% YoY); net loss ($55.7M) vs ($49.5M); adj. EBITDA loss narrowed to ($11.0M) from ($24.4M).
FY2025 revenue guidance $224M-$230M (7-10% growth); expects breakeven adj. EBITDA for full year.
Entry into osteotomy market with Nanoplasty and Percuplasty 3D bunion systems; 280 new active surgeons added in 2024.
Cash $75.7M plus $26M revolver access; patent portfolio 97 granted, 88 pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.